Compare PPCB & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPCB | VTAK |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.9M |
| IPO Year | N/A | 2018 |
| Metric | PPCB | VTAK |
|---|---|---|
| Price | $0.19 | $1.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 65.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $442,000.00 |
| Revenue This Year | N/A | $822.86 |
| Revenue Next Year | N/A | $168.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $0.16 | $0.15 |
| 52 Week High | $10.69 | $4.31 |
| Indicator | PPCB | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 44.96 |
| Support Level | $0.18 | $1.52 |
| Resistance Level | $0.40 | $2.05 |
| Average True Range (ATR) | 0.03 | 0.19 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 22.28 | 60.47 |
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.